UPCC 23423: Full Protocol Title A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This study tests an investigational drug called LANRA as a possible treatment for people with relapsed or refractory FLT3-mutated AML.
This study will take place in 2 parts. In Part 1 (dose escalation), the main purpose is to determine the maximal dose of LANRA that can be safely administered and is adequately tolerated when given in combination with gilteritinib.
In Part 2, the safety of the combination of LANRA at the maximally tolerated dose and gilteritinib will be further studied.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854345
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
